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A b s t r a c t 
Introduction: Mitral regurgitation (MR) of varying degrees and mechanisms is a common finding in patients with aortic stenosis 
with different improvement after transcatheter aortic valve implantation (TAVI).
Aim: To evaluate the impact of TAVI on mitral complex geometry and the degree of MR.
Material and methods: A total of 31 patients (29.0% males) with severe aortic stenosis and moderate or severe MR at the base-
line who underwent TAVI were included in this study. Clinical and echocardiographic characteristics were determined at baseline 
and at 6 and 12 months.
Results: After TAVI, decrease of MR vena contracta width (p = 0.00002, p = 0.00004), aorto-mural mitral annulus diameter 
(p = 0.00008, p = 0.02), increase of mitral annular plane systolic excursion (p = 0.0004, p = 0.0003), left ventricular stroke volume 
(p = 0.0003, p = 0.0004), ejection fraction (p = 0.0004, p = 0.01) and decrease of major dimension of left ventricle in three chamber 
view (p = 0.05, p = 0.002) were observed in patients at both time points. Additionally, we observed a decrease of distance between 
the head of the papillary muscles (p = 0.003) at 6 months and a decrease of left atrium volume index (p = 0.01) and systolic pulmo-
nary artery pressure (p = 0.01) at 12 months.
Conclusions: Patients with moderate or severe MR undergoing TAVI achieved significant improvement of mitral valve complex 
function resulting in the reduction of MR degree.
Key words: transcatheter aortic valve implantation, mitral regurgitation, mitral valve complex, aortic stenosis.
S u m m a r y
In patients with severe aortic stenosis and moderate or severe mitral regurgitation undergoing a transcatheter aortic valve im-
plantation procedure significant reductions of symptoms and improvement of mitral valve complex function resulting in the reduc-
tion of mitral regurgitation degree are observed, as well as a significant improvement of the left ventricle geometry and functions.
Introduction
The mitral valve apparatus is a  complex consisting 
of the annulus, leaflets, commissures, tendinous cords, 
papillary muscles and the left atrial and ventricular walls 
[1, 2]. Assessment of all components of the mitral ap-
paratus is necessary to determine the mechanism of its 
incompetency. Mitral regurgitation (MR) can be classified 
as primary (due to structural abnormalities of the valve), 
secondary (functional), associated with left ventricle dys-
function (ischemic and non-ischemic MR) and as a con-
sequence of atrial fibrillation (AF).
MR is frequently present in patients with severe 
aortic stenosis (AS) [3]. Mitral valve deformation and 
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tethering, as well as an increase in transmitral pressure 
gradient caused by AS and increased left ventricle (LV) 
pressure, all contribute to MR [4]. Additionally, with in-
creasing age, the incidence of AS and coronary artery 
disease may lead to development of functional ischemic 
MR [5, 6]. In the PARTNER trial, the incidence of concom-
itant moderate-to-severe MR in patients with severe AS 
was approximately 20% [7, 8]. However, the necessity of 
intervention for both valves may increase the risk of op-
eration to an unacceptable level, especially in high-risk 
patients. Transcatheter aortic valve implantation (TAVI) is 
a  feasible option for the treatment of severe AS in pa-
tients at high risk of conventional surgical aortic valve 
replacement [9–11].
Aim
In this study, we sought to assess the impact of TAVI 
on geometry and function of the mitral apparatus in 
patients with at least a moderate degree of MR in the 
pre-procedural transthoracic echocardiography (TTE). 
Detailed aims of this study were: 1) to characterize the 
degree of MR by TTE at 6- and 12-month follow-up after 
TAVI in patients with moderate or severe MR before TAVI; 
2) to investigate the impact of TAVI on TTE parameters 
assessing geometry and function of the mitral valve com-
plex: mitral annulus, left atrium and left ventricle. 
Material and methods
Study population
This study was approved by the Bioethical Committee 
of the Jagiellonian University, Cracow, Poland. The study 
protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki. All patients provided informed 
consent for participation in the study. We analyzed all 
patients with severe AS admitted to the Department of 
Cardiology and Cardiovascular Interventions, University 
Hospital in Krakow between January 2015 and December 
2016. We included 31 patients (29.0% males, 82.1 ±5.2 
years old) with severe AS and concomitant moderate or 
severe MR, recognized during TTE according to the rec-
ommendations for the echocardiographic assessment of 
native valvular regurgitation [12]. Patients without a suf-
ficient acoustic window were excluded. All patients had 
high risk or serious contraindications for surgical aortic 
valve replacement and were qualified for TAVI by a multi-
disciplinary “Heart Team”. Clinical and TTE follow-up was 
conducted through control visits of the patient at 6 and 
12 months after TAVI (Edwards Sapien XT valve; Edwards 
Lifesciences, Irvine, CA, USA, Evolut R Medtronic Scientif-
ic, Minneapolis, MN, USA).
Echocardiographic assessment
All patients underwent TTE, including M-mode, 
two-dimensional, three-dimensional, and Doppler im-
aging, at baseline and during follow-up. Close attention 
was paid to all acquisition settings in order to maximize 
image quality. For better visualization of mitral and aor-
tic valve anatomy and function, two-dimensional and 
three-dimensional transesophageal echocardiography 
(TEE) was performed at baseline. All TTE and TEE exam-
inations were performed using Vivid E9 (GE Healthcare, 
Waukesha, WI, USA). The post-processing evaluation was 
performed using a dedicated workstation (EchoPAC, GE 
Healthcare, Waukesha, WI, USA). The linear measure-
ments were taken using virtual calipers. The measure-
ments were performed according to the current recom-
mendations [12, 13]. 
The following qualitative and quantitative echocardi-
ography parameters were performed to assess the sever-
ity of MR: vena contracta (VC) width (in the case of mul-
tiple jets: vena contracta of the dominant jet) and peak 
E-wave; to assess mitral valve geometry: mitral annulus 
diameters at end-diastole: aorto-mural diameter in para-
sternal long-axis TTE view and intercommissural diame-
ter in the modified apical two-chamber view; aorto-mural 
annulus/anterior leaflet ratio; maximal and mean trans-
valvular mitral gradient; maximal and mean transvalvu-
lar aortic gradient; peak aortic valve velocity (Vmax); and 
aortic valve area (AVA). The antero-mural diameter of the 
mitral annulus > 35 mm or the aorto-mural annulus/an-
terior leaflet ratio > 1.3 was considered to indicate mitral 
annular dilatation [12, 14].
Additionally, particular left ventricle geometry and 
function parameters were evaluated: end-diastolic and 
end-systolic left ventricle diameters in parasternal long-ax-
is; left ventricle sphericity index in apical four-chamber 
view; major left ventricle dimension in three-chamber 
view; distance between heads of left ventricular papil-
lary muscles in end-diastolic phase; left ventricle ejection 
fraction; stroke volume; and mitral annular plane systolic 
excursion. Other parameters include left atrium diameter 
in parasternal long-axis view; left atrium indexed volume; 
right atrium area and indexed volume; right ventricle 
linear dimension (maximal transversal dimension in the 
basal one third of right ventricle inflow at end-diastole); 
systolic pulmonary artery pressure; and grade of tricuspid 
regurgitation.
Statistical analysis 
Standard descriptive statistical methods were used. 
The data were presented as mean values with their cor-
responding standard deviations. The normality of the 
data was assessed with the Shapiro-Wilk test. One-way 
analysis with the unpaired two-sample T-test (for normal 
distribution) or the Mann-Whitney U  test (for non-nor-
mally distributed data) was applied for quantitative 
variables. The analysis of variance (ANOVA) or non-para-
metric Kruskal-Wallis test was used to compare values 
between different groups. Detailed comparisons were 
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performed using Tukey’s post hoc analyses. Qualitative 
variables were compared using the χ2 (chi-squared) test 
of proportions with Bonferroni correction to account for 
multiple comparisons. We performed statistical analyses 
with Statisticav13 (StatSoft Inc., Tulsa, OK, USA). The sta-
tistical significance was set at a p-value lower than 0.05.
Results
The baseline clinical characteristics of patients are 
shown in Table I. At baseline, patients presented heart 
failure symptoms that were mainly (58.1%) in class III 
of the New York Heart Association (NYHA) Functional 
Classification (Table II). Moderate MR was diagnosed in 
93.5% of patients and severe in 6.5%. Calcifications in 
the mitral valve annulus were found in 61.3% of patients 
and in mitral valve leaflets in 22.6% of patients. Annular 
mitral dilatation was identified in 64.5% of patients. MR 
was accompanied by moderate and severe TR in 41.9% 
and 9.7% of patients, respectively.
One patient died 2 months after TAVI and therefore 
the follow-up group at 6 and 12 months consisted of 
30 patients. Table II presents clinical and echocardio-
graphic data at baseline and during follow-up. A signif-
icant decrease of heart failure symptoms assessed with 
NYHA class was observed both 6 and 12 months after 
TAVI as compared to baseline (Table II; p < 0.05). Several 
critical MR parameters showed significant improvement 
after the procedure, which included a  decrease in VC 
(baseline: 5.9 ±1.5 mm vs. 6 months: 3.8 ±1.6 mm vs. 
12 months: 3.2 ±1.4 mm, Table II, p < 0.001).
All patients in the studied group achieved a signifi-
cant increase of AVA (p = 0.000006, p = 0.00002) and 
a decrease of maximal (p = 0.000003, p = 0.000008) and 
mean (p = 0.000003, p = 0.000008) transvalvular aortic 
gradient. After TAVI, decrease of MR, especially VC width 
(p = 0.00002, p = 0.00004) and aorto-mural mitral an-
nulus diameter (p = 0.00008, p = 0.02), was achieved. 
Additionally, an increase of mitral annular plane systol-
ic excursion (p = 0.0004, p = 0.0003), left ventricular 
stroke volume (LVSV) (p = 0.0003, p = 0.0004) and LVEF 
(p = 0.0004, p = 0.01) and a decrease of major dimen-
sion of the left ventricle in three-chamber view (p = 0.05, 
p = 0.002) and left ventricular end-systolic diameter 
(LVESD) (p = 0.004, p = 0.02) were observed in patients 
at both time points. We observed a decrease of distance 
between the head of the papillary muscles (p = 0.003) 
at 6 months and a decrease of left atrium volume index 
(LAVi) (p = 0.01) and systolic pulmonary artery pressure 
(sPAP) (p = 0.01) at 12 months. Detailed TTE data are 
listed in Table II.
Discussion
Mitral regurgitation in patients with severe SA re-
ferred for TAVI may have functional, organic, or complex 
etiology. The latter is most frequent in the group of elder-
ly patients. Degeneration and calcifications of the valve 
are frequent and usually affect the leaflets, tendinous 
cord and annulus [15]. In the studied group, calcifications 
of the mitral annulus dominated (61.3%). On the oth-
er hand, coronary heart disease is common in patients 
after TAVI, including in the form of previous myocardial 
infarction, which may be the cause of left ventricular re-
modeling and ischemic MR. Additionally, severe SA with 
elevated end-systolic LV pressure may aggravate suben-
docardial ischemia with deterioration of the left ventricle 
function and cause changes of geometry which may also 
be a component of non-ischemic functional MR.
Both mentioned components of functional MR led to 
mitral apparatus geometry deformation, including leaflet 
restriction, enlargement of the mitral ring, and increase 
in distance between papillary muscles. Considering the 
complexity of the MR pathomechanism in patients with 
AS and improvement of left ventricular function after 
TAVI, a reduction in the significance of MR after the pro-
cedure should be expected [16].
There has been much discussion regarding the reduc-
tion of MR after isolated aortic valve replacement. Follow-
ing surgical aortic valve replacement, improvement in MR 
was reported in 27–82% of the patients [17]. Webb et al. 
reported an improvement in MR in 24 out of the 50 pa-
tients (48%) with moderate to severe MR following the 
implantation of the Edwards Sapien Valve [18]. In another 
Table I. Baseline clinical characteristics of patients
Variable Number (%)  
or mean ± SD
Age, mean ± SD [years] 82.1 ±5.2
Coronary artery disease confirmed  
in angiography, n (%)
20 (64.5)
Previous myocardial infarction, n (%) 9 (29.0)
Previous percutaneous coronary intervention,  
n (%)
14 (45.2)
Previous coronary artery bypass grafting, n (%) 4 (12.9)
Cardiac resynchronization therapy, n (%) 0
Pacemaker, n (%) 7 (22.6)
Arterial hypertension, n (%) 28 (90.3)
Diabetes mellitus type II, n (%) 9 (29.0)
Atrial fibrillation, n (%) 20 (64.5)
Hyperlipidemia, n (%) 12 (38.7)
Ever-smoker, n (%) 2 (6.5)
GFR [ml/min/1.73 m2] 55.4 ±15.4
Previous stroke/transient ischemic attack, n (%) 1 (9.7)
Body mass index, mean ± SD [kg/m2] 26.1 ±3.7
Body surface area, mean ± SD [m2] 1.7 ±0.2
SD – standard deviation.
Danuta Sorysz et al. Mitral regurgitation after TAVI
303Advances in Interventional Cardiology 2020; 16, 3 (61)
study in 171 patients with MR grade ≥ 2, 29% improved 
to MR grade ≤ 1. TAVI had no influence on MR grade at 
follow-up [19]. Functional MR, coronary artery disease and 
absence of atrial fibrillation have been identified as predic-
tors of reduction of MR after TAVI [20]. Our study shows 
that TAVI improves the grade of MR (Figure 1) at 6 and 
12 months, which could be a result of improvement in ge-
ometry of the mitral complex and left ventricle function. 
Only 9 (30%) patients did not achieve a reduction of MR 
grade at any analyzed time points. A significant reduction 
Table II. Results of obtained echocardiographic data (mean±standard deviation) at baseline and during follow-up
Parameter Baseline 6 months P-value  
baseline vs.  
6 months
12 months P-value  
baseline vs.  
12 months
Mitral regurgitation, n (%):
Trivial 0 2 0.01* 3 0.054
Mild 0 16 16
Moderate 29 12 11
Severe 1 0 0
VC [mm] 5.9 ±1.5 3.8 ±1.6 0.00002* 3.2 ±1.4 0.00004*
E [m/s] 1.0 ±0.2 1.0 ±0.3 0.4 1.0 ±0.2 0.6
Intercommissural mitral annulus diameter [mm] 31.7 ±4.4 30.0 ±4.5 0.01* 30.7 ±4.7 0.1
Aorto-mural mitral annulus diameter [mm] 29.0 ±5.6 27.1 ±5.2 0.00008* 27.7 ±5.1 0.02*
Aorto-mural mitral annulus/anterior leaflet ratio 1.5 ±0.3 1.4 ±0.31 0.4 1.4 ±0.29 0.03*
PGmv [mm Hg] 6.3 ±2.0 8.3 ±4.4 0.08* 7.2 ±3.6 0.2
MPGmv [mm Hg] 2.8 ±1.0 3.3 ±1.6 0.1 2.6 ±1.3 0.6
PGao [mm Hg] 82.2 ±36.8 23.2 ±10.9 0. 000003* 23.9 ±10.3 0.000008*
MPGao [mm Hg] 50.9 ±23.5 12.5 ±6.2 0. 000003* 13.8 ±6.5 0.000008*
Vmax 4.4 ±1.0 2.3 ±0.5 0. 000003* 2.4 ±0.5 0.000006*
AVA [cm2] 0.58 ±0.2 1.5 ±0.3 0.000006* 1.4 ±0.3 0.00002*
LVEDD [mm] 48.9 ±13.6 47.1 ±9.5 0.3 46.5 ±7.7 0.02
LVESD [mm] 36.7 ±12.4 31.8 ±8.5 0.004* 32.7 ±8.9 0.02*
LVSV [ml] 61.3 ±15.0 75.3 ±18.8 0.0003* 70.8 ±13.6 0.004*
SFi 0.62 ±0.086 0.59 ±0.089 0.6 0.60 ±0.086 0.5
Major dimension of LV in three-chamber view [mm] 77.9 ±10.9 76.3 ±9.6 0.047* 72.8 ±8.2 0.002*
Distance between head of papillary muscle 23.5 ±6.0 20.7 ±5.1 0.003* 21.0 ±7.0 0.1
LVEF (%) 51.6 ±17.1 59.2 ±13.3 0.0004* 59.5 ±13.3 0.01*
LAd [cm] 4.8 ±0.6 4.9 ±0.7 0.8 4.8 ±0.6 0.6
LAVi [ml/m2] 74.8 ±19.0 68.7 ±18.8 0.2 62.9 ±18.5 0.01*
RAA [cm2] 18.0 ±8.0 19.8 ±6.8 0.99 19.6 ±5.7 0.9
RAVi [ml/m2] 38.5 ±16.2 38.2 ±20.8 0.7 35.3 ±14.3 0.3
RV dimension [mm] 37.1 ±6.3 33.4 ±9.6 0.125 36.8 ±5.4 0.95
sPAP [mm Hg] 52.6 ±11.9 52.3 ±15.6 0.97 45.2 ±11.1 0.01*
MAPSE [mm] 11.1 ±2.5 13.1 ±2.6 0.0004* 13.6 ±2.4 0.0003*
Tricuspid regurgitation:
Trivial 2 6 0.3 8 0.07
Mild 12 14 11
Moderate 12 7 8
Severe 3 3 3
NYHA:
I 0 7 0.0002* 8 0.002*
II 9 19 19
III 18 4 3
IV 1 0 0
N – number of samples, VC – vena contracta width LV – left ventricle, RV – right ventricle, LA – left atrium, RA – right atrium, PGmv – maximal transvalvular mitral 
gradient, MPGmv – mean transvalvular mitral gradient, PGao – maximal transvalvular aortic gradient, MPGao – mean transvalvular aortic gradient , Vmax – peak 
aortic valve velocity, LVEDD – end-diastolic LV diameter, LVESD – left ventricular end-systolic diameter, LVSV – left ventricular stroke volume, SFi – LV sphericity index, 
LVEF – LV ejection fraction, LAd – left atrium diameter, LAVi – left atrium volume index, RAA – right atrium area, RAVi – right atrium volume index, sPAP – systolic 
pulmonary artery pressure, MAPSE – mitral annular plane systolic excursion, *statistically significant.
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of the diameter of the mitral annulus and distance be-
tween the heads of the papillary muscles was observed. 
The detailed study of Tayyareci et al. also showed the im-
portance of mitral annulus diameter and area reduction 
(2D and 3D analysis) in the group with MR improvement. 
Moreover, they observed no effect of TAVI on MR in the 
group with restriction of mitral leaflets, which is a conse-
quence of mitral complex geometry change, as the greater 
distance between papillary muscles [16]. In our study, a sig-
nificant decrease of sPAP was observed, although it may be 
the result of aortic valve implantation as well as a decrease 
in the significance of MR. This was reflected in a significant 
improvement in exercise capacity (NYHA class).
As coronary artery disease was present in two-thirds 
of patients and one-third of patients had a  history of 
myocardial infarction, the functional component of the 
MR etiology seems to be the most frequent in the studied 
group. A significant reduction in left ventricular diameter 
and an improvement in left ventricular systolic function 
were observed, reflected in an increase in LVEF and mitral 
annular plane systolic excursion (MAPSE). Interestingly, 
the reduction in end-diastolic dimension achieves statis-
tical significance 1 year after the procedure, in contrast 
to the end-diastolic dimension and ejection fraction. Rel-
atively immediate increase in ejection fraction observed 
as early as 6 months after TAVI may be the result of a sig-
nificant decrease in afterload and transvalvular gradients 
after TAVI valve implantation. In contrast, the process of 
reversing negative remodeling is long-lasting, and hence 
the reduction in end-diastolic volume was confirmed only 
in an annual follow-up. The observed increase in LVSV 
may be caused by both an increase in LVEF and a reduc-
tion in the significance of MR.
The present study has two major limitations. The 
most important one is its single-center character and 
the relatively small sample size. To eliminate these disad-
vantages, further, large, multicenter clinical studies with 
extended follow-up are required to confirm the findings 
of our study. 
Conclusions
Patients with severe AS and moderate or severe 
MR undergoing TAVI achieved a  significant reduction 
of symptoms and improvement of mitral valve complex 
function resulting in the reduction of MR degree. Further-
more, a significant improvement in the left ventricle ge-
ometry and function was achieved.
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